RAC Stock Overview
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.81 |
| 52 Week High | AU$2.09 |
| 52 Week Low | AU$0.64 |
| Beta | 1.74 |
| 11 Month Change | 4.34% |
| 3 Month Change | 0% |
| 1 Year Change | 94.09% |
| 33 Year Change | -46.60% |
| 5 Year Change | 1,288.46% |
| Change since IPO | 581.13% |
Recent News & Updates
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?
Aug 26
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully
May 10Recent updates
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?
Aug 26We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully
May 10We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate
Jan 23Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 05Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth
Jun 20We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow
Feb 17Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 14Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Apr 01We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Apr 05What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?
Mar 01How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?
Jan 07
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 6.2% | -2.0% | 0.3% |
| 1Y | 94.1% | 15.2% | 15.1% |
Return vs Industry: RAC exceeded the Australian Biotechs industry which returned 15.2% over the past year.
Return vs Market: RAC exceeded the Australian Market which returned 15.1% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: RAC has not had significant price volatility in the past 3 months.
Volatility Over Time: RAC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.raceoncology.com |
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.
Race Oncology Limited Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market cap | AU$312.73m |
| Earnings (TTM) | -AU$13.82m |
| Revenue (TTM) | AU$4.00m |
76.8x
P/S Ratio-22.3x
P/E RatioIs RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$4.00m |
| Cost of Revenue | AU$2.61m |
| Gross Profit | AU$1.39m |
| Other Expenses | AU$15.21m |
| Earnings | -AU$13.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 34.72% |
| Net Profit Margin | -345.18% |
| Debt/Equity Ratio | 0% |
How did RAC perform over the long term?
See historical performance and comparison